Compare Invesco NASDAQ 100 ETF (QQQM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Tango Therapeutics Inc. — how do they compare? Invesco NASDAQ 100 ETF trades at $296.27 (market cap $111.77B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 29.8× Tango Therapeutics Inc.'s market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco NASDAQ 100 ETF for 56 Days and Tango Therapeutics Inc. for 0 Days on average.
| QQQM | TNGX | |
|---|---|---|
Market Cap | $111.77B | $3.75B |
Volume | 2,346,098 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $312.76 | $32.90 |
52-Week Low | $229.87 | $7.50 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $306.18, down 0.33% with a bullish technical signal from moving averages. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads may offset this benefit. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show neutral oscillators with key support at $304-$306 and resistance at $308-$310.
QQQM offers exposure to Nasdaq-100 growth stocks with competitive fees, but faces competition from alternatives like SCHG and QQQE. The ETF's performance depends on technology sector leadership, with concentration risk in top holdings. Recent news highlights tax implications of similar ETFs, emphasizing the importance of understanding distribution characteristics for long-term returns.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
